Vaccination
Vaccination
Pediatric & adult schedules · EU / Russia / CDC · v0.4.0
Audience
Schedule
Evidence-based EU baseline built from widely used EU/EEA patterns and ECDC Vaccine Scheduler principles (not a single country schedule). Optional vaccines are marked as country-dependent; always verify local programme.
| Age | Vaccine | Dose |
|---|---|---|
| Birth | Hep B Birth dose is universal in some EU/EEA programmes; at minimum recommended for infants of HBsAg-positive mothers (local policy). | #1 |
| Neonatal (country-specific) | BCG Offered in TB-endemic EU countries; not universal across EU. | #1 |
| 1 month | Hep B | #2 |
| 2 months | DTaP-IPV-Hib | #1 |
| PCV | #1 | |
| RV Country-dependent; adhere to product age limits for starting/completing the series. | #1 | |
| MenB Country-dependent (e.g. UK and selected EU/EEA programmes). | #1 | |
| 3 months | RV | #2 |
| 4 months | DTaP-IPV-Hib Many EU/EEA programmes use a 2+1 primary schedule (2, 4, 11–12 months) for hexavalent combinations; some use 3+1 (2, 3, 4, 11–12 months). | #2 |
| PCV Common EU/EEA pattern is 2+1 PCV (2, 4, 11–12 months); some programmes use 3+1. | #2 | |
| MenB | #2 | |
| 6 months | Hep B | #3 |
| 11–12 months (booster) | DTaP-IPV-Hib | #3 |
| 12 months | MMR | #1 |
| 12–15 months | Varicella Country-dependent (not universal across EU/EEA). | #1 |
| 12 months (booster) | PCV | #3 |
| MenB | #3 | |
| 4–6 years (preschool booster) | DTaP-IPV-Hib | #4 |
| 4–6 years | MMR | #2 |
| Varicella Country-dependent; if used, ensure 2-dose series (interval depends on age at start). | #2 | |
| 9–14 years (2-dose series) | HPV Country-dependent; if started ≥15 years or immunocompromised, use 3-dose schedule. | #1 |
Contraindications
True contraindication
Do not vaccinate; re-evaluate only if diagnosis was incorrect or condition resolved per guidance.
- Anaphylaxis to prior dose or vaccine component
- Encephalopathy after pertussis-containing vaccine
Precaution
Benefits may outweigh risks; vaccinate with monitoring or specialist advice.
- Moderate acute illness (with or without fever)
- Recent immunoglobulin or blood product (live vaccines)
Postpone
Defer until recovered or interval elapsed; not a permanent contraindication.
- Severe acute illness — vaccinate after recovery
- High fever and systemic symptoms — postpone until stable
Not a contraindication (common myths)
These situations usually do not require delaying routine vaccination (unless otherwise specified by local guidance).
- Mild acute illness (e.g., rhinitis) with low/no fever
- Antibiotic therapy
Catch-up (basics)
3-dose series: 0, 1, 6 months. Minimum intervals: dose1→2 ≥4 weeks; dose2→3 ≥8 weeks; dose1→3 ≥16 weeks; final dose should be at age ≥24 weeks (product/policy-dependent).
If first dose given <12 months: count as dose 0; repeat at ≥12 months and second dose ≥4 weeks later. Unvaccinated ≥12 months: 2 doses ≥4 weeks apart.
Primary series minimum intervals: dose1→2 ≥4 weeks; dose2→3 ≥4 weeks. Booster: ≥6 months after dose3 (programme-dependent). Pertussis-containing vaccines have upper age limits (often <7 years); after that use Td/Tdap per policy. Hib catch-up is age-dependent (≥15 months often 1 dose; 12–14 months usually 2 doses ≥8 weeks apart; <12 months needs multiple doses + booster).
Minimum interval between doses in infancy: ≥4 weeks (programme/product-dependent). Typical catch-up patterns: start 7–11 months → 2 doses ≥4 weeks apart + booster after 12 months (≥8 weeks later); start 12–23 months → 2 doses ≥8 weeks apart; start ≥24 months (healthy) → often 1 dose (high-risk may need more).
2 doses if not immune. Minimum interval: if <13 years, give dose2 ≥3 months after dose1 (some programmes accept ≥4 weeks); if ≥13 years, dose2 ≥4 weeks after dose1. If MMR and varicella not given same day, separate live vaccines by ≥4 weeks.
If started before 15 years (immunocompetent): 2 doses 6–12 months apart (minimum 5 months). If started at ≥15 years or immunocompromised: 3 doses (e.g., 0, 1–2, 6 months) with minimum intervals per product/SPC.
If primary series incomplete: complete 3-dose tetanus–diphtheria–containing series with one dose as Tdap; then boosters every 10 years.
Unvaccinated adults 19–59: start standard 2- or 3-dose HepB series (product-specific); ≥60 risk-based or shared decision (CDC).
Through age 26 complete series; 27–45 only after shared clinical decision-making.
Sources
- • ESPID — European Society for Paediatric Infectious Diseases
- • WHO Immunization Schedules
- • ECDC Vaccine Scheduler
+ 4 more
- • Russian MoH — National Immunization Calendar
- • ÚVZ SR — Public Health Authority of the Slovak Republic
- • CDC Adult Immunization Schedule 2025 (2025)
- • Минздрав РФ — национальный календарь профилактических прививок (1122н) (2021)